Cargando…

Toxin-Based Targeted Therapy for Malignant Brain Tumors

Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandramohan, Vidyalakshmi, Sampson, John H., Pastan, Ira, Bigner, Darell D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287048/
https://www.ncbi.nlm.nih.gov/pubmed/22400035
http://dx.doi.org/10.1155/2012/480429
_version_ 1782224610522038272
author Chandramohan, Vidyalakshmi
Sampson, John H.
Pastan, Ira
Bigner, Darell D.
author_facet Chandramohan, Vidyalakshmi
Sampson, John H.
Pastan, Ira
Bigner, Darell D.
author_sort Chandramohan, Vidyalakshmi
collection PubMed
description Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages.
format Online
Article
Text
id pubmed-3287048
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32870482012-03-07 Toxin-Based Targeted Therapy for Malignant Brain Tumors Chandramohan, Vidyalakshmi Sampson, John H. Pastan, Ira Bigner, Darell D. Clin Dev Immunol Review Article Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages. Hindawi Publishing Corporation 2012 2012-02-09 /pmc/articles/PMC3287048/ /pubmed/22400035 http://dx.doi.org/10.1155/2012/480429 Text en Copyright © 2012 Vidyalakshmi Chandramohan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chandramohan, Vidyalakshmi
Sampson, John H.
Pastan, Ira
Bigner, Darell D.
Toxin-Based Targeted Therapy for Malignant Brain Tumors
title Toxin-Based Targeted Therapy for Malignant Brain Tumors
title_full Toxin-Based Targeted Therapy for Malignant Brain Tumors
title_fullStr Toxin-Based Targeted Therapy for Malignant Brain Tumors
title_full_unstemmed Toxin-Based Targeted Therapy for Malignant Brain Tumors
title_short Toxin-Based Targeted Therapy for Malignant Brain Tumors
title_sort toxin-based targeted therapy for malignant brain tumors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287048/
https://www.ncbi.nlm.nih.gov/pubmed/22400035
http://dx.doi.org/10.1155/2012/480429
work_keys_str_mv AT chandramohanvidyalakshmi toxinbasedtargetedtherapyformalignantbraintumors
AT sampsonjohnh toxinbasedtargetedtherapyformalignantbraintumors
AT pastanira toxinbasedtargetedtherapyformalignantbraintumors
AT bignerdarelld toxinbasedtargetedtherapyformalignantbraintumors